JP2016512527A - 動脈瘤性くも膜下出血の合併症を治療するための組成物およびそれらの使用 - Google Patents
動脈瘤性くも膜下出血の合併症を治療するための組成物およびそれらの使用 Download PDFInfo
- Publication number
- JP2016512527A JP2016512527A JP2016501330A JP2016501330A JP2016512527A JP 2016512527 A JP2016512527 A JP 2016512527A JP 2016501330 A JP2016501330 A JP 2016501330A JP 2016501330 A JP2016501330 A JP 2016501330A JP 2016512527 A JP2016512527 A JP 2016512527A
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- cerebral
- use according
- artery
- sah
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/793,767 US10092524B2 (en) | 2008-06-11 | 2013-03-11 | Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage |
| US13/793,767 | 2013-03-11 | ||
| PCT/US2014/023748 WO2014164904A1 (en) | 2013-03-11 | 2014-03-11 | Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016512527A true JP2016512527A (ja) | 2016-04-28 |
| JP2016512527A5 JP2016512527A5 (cg-RX-API-DMAC7.html) | 2017-02-16 |
Family
ID=49157870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501330A Pending JP2016512527A (ja) | 2013-03-11 | 2014-03-11 | 動脈瘤性くも膜下出血の合併症を治療するための組成物およびそれらの使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10092524B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2968166A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2016512527A (cg-RX-API-DMAC7.html) |
| KR (1) | KR101902319B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN105324108A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2014248877A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112015022218A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2905327A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2528801A (cg-RX-API-DMAC7.html) |
| HK (1) | HK1216002A1 (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ629730A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2015143206A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201507398XA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2014164904A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10092524B2 (en) | 2008-06-11 | 2018-10-09 | Edge Therapeutics, Inc. | Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage |
| AU2012240131B2 (en) | 2011-04-05 | 2017-07-20 | Edge Therapeutics | Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow |
| JP2018522942A (ja) * | 2015-05-29 | 2018-08-16 | エッジ セラピューティクス インコーポレイテッド | 視力障害を低減するための組成物及び方法 |
| WO2017176914A1 (en) * | 2016-04-07 | 2017-10-12 | Edge Therapeutics, Inc. | Formulations of site-specific, microparticulate compositions and their use to improve outcome after aneurysmal subarachnoid hemorrhage |
| CN108403629B (zh) * | 2018-04-26 | 2019-11-05 | 徐州医科大学 | 一种尼莫地平口服长效悬浮液及其制备方法 |
| US12697299B2 (en) * | 2019-05-07 | 2026-08-04 | Yale University | Maximizing distribution and minimizing washout of injectates in bone and method for enhanced aspirate extraction |
| WO2020235947A1 (ko) * | 2019-05-22 | 2020-11-26 | 경북대학교 산학협력단 | Cacb1 유래 펩타이드, Cacb1 유래 펩타이드의 변이체 및 이의 용도 |
| US20210260334A1 (en) * | 2020-02-20 | 2021-08-26 | Postsurgical Therapeutics, Inc. | Brain drug delivery system and method |
| WO2021262725A1 (en) * | 2020-06-22 | 2021-12-30 | Curelator, Inc. | Systems and methods for segmentation of a user population based on time-based variations in biomarker levels |
| US11452690B1 (en) | 2021-01-27 | 2022-09-27 | ECI Pharmaceuticals, LLC | Oral liquid compositions comprising amlodipine besylate and methods of using the same |
| WO2022185235A1 (en) * | 2021-03-03 | 2022-09-09 | Crannmed Limited | Alginate based particles as a temporary embolic agent |
| WO2025151741A1 (en) * | 2024-01-10 | 2025-07-17 | Brown David Donaldson | Methods of treating migraine headache or tension headache with hyaluronic acid |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012109664A1 (en) * | 2011-02-11 | 2012-08-16 | Edge Therapeutics | Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage |
| WO2012138854A1 (en) * | 2011-04-05 | 2012-10-11 | Edge Therapeutics | Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4757128A (en) | 1986-08-01 | 1988-07-12 | Massachusetts Institute Of Technology | High molecular weight polyanhydride and preparation thereof |
| US4937270A (en) | 1987-09-18 | 1990-06-26 | Genzyme Corporation | Water insoluble derivatives of hyaluronic acid |
| US5527893A (en) | 1987-09-18 | 1996-06-18 | Genzyme Corporation | Water insoluble derivatives of polyanionic polysaccharides |
| WO1990013361A1 (en) | 1989-05-04 | 1990-11-15 | Southern Research Institute | Improved encapsulation process and products therefrom |
| US5650489A (en) | 1990-07-02 | 1997-07-22 | The Arizona Board Of Regents | Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof |
| IT1243390B (it) | 1990-11-22 | 1994-06-10 | Vectorpharma Int | Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione. |
| US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
| CA2180526A1 (en) | 1994-01-05 | 1995-07-13 | Joseph C. Hogan, Jr. | Method of identifying chemical compounds having selected properties for a particular application |
| US5712171A (en) | 1995-01-20 | 1998-01-27 | Arqule, Inc. | Method of generating a plurality of chemical compounds in a spatially arranged array |
| US5747058A (en) | 1995-06-07 | 1998-05-05 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system |
| US5968542A (en) | 1995-06-07 | 1999-10-19 | Southern Biosystems, Inc. | High viscosity liquid controlled delivery system as a device |
| AT404429B (de) | 1995-06-09 | 1998-11-25 | Immuno Ag | Anti-plasma-antikörper-präparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| PL189698B1 (pl) | 1996-03-12 | 2005-09-30 | Pg Txl Co | Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania |
| ATE318580T1 (de) | 1996-12-20 | 2006-03-15 | Alza Corp | Gelzusammensetzungen und verfahren |
| CA2296056A1 (en) | 1997-07-10 | 1999-01-21 | Keith Baker | Methods for universally distributing therapeutic agents to the brain |
| AU9596698A (en) | 1997-10-15 | 1999-05-03 | Thomas Jefferson University | Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal |
| JP2000070366A (ja) | 1998-09-02 | 2000-03-07 | Arute:Kk | 容器兼用注射器及び容器兼用注射器への凍結乾燥製剤の封入方法 |
| US20050214227A1 (en) * | 1999-03-08 | 2005-09-29 | Powderject Research Limited | Microparticle formulations for sustained-release of bioactive compounds |
| US7651703B2 (en) | 1999-10-15 | 2010-01-26 | Genentech, Inc. | Injection vehicle for polymer-based formulations |
| US6284283B1 (en) | 1999-10-21 | 2001-09-04 | Alkermes Controlled Therapeutics, Inc. | Method of producing sub-micron particles of biologically active agents and uses thereof |
| AU2607701A (en) | 1999-12-29 | 2001-07-09 | Regeneration Technologies, Inc. | System for reconstituting pastes and methods of using same |
| JP2003520830A (ja) | 2000-01-25 | 2003-07-08 | エドワーズ ライフサイエンシーズ コーポレイション | 再狭窄および吻合内膜過形成処置のための送達系 |
| US6495164B1 (en) | 2000-05-25 | 2002-12-17 | Alkermes Controlled Therapeutics, Inc. I | Preparation of injectable suspensions having improved injectability |
| JP2002003406A (ja) | 2000-06-21 | 2002-01-09 | Sankyo Co Ltd | 脳血管攣縮予防製剤 |
| US20030032676A1 (en) | 2001-08-09 | 2003-02-13 | Kimelberg Harold K. | Drugs for treatment of cerebral injury and methods of use thereof |
| WO2003020208A2 (en) | 2001-08-31 | 2003-03-13 | Neuron Therapeutics, Inc. | Treatment of neurologic hemorrhage |
| US20040235801A1 (en) | 2001-10-25 | 2004-11-25 | Jean-Pierre Julien | Therapy for stroke |
| ATE470351T1 (de) | 2001-11-22 | 2010-06-15 | Japan Science & Tech Agency | Nichtmenschliches tiermodell, das nicht auf eine immunopotenzierende synthetische verbindung anspricht |
| AU2003219922B2 (en) | 2002-02-27 | 2009-09-10 | Pharmain Corporation | Compositions for delivery of therapeutics and other materials, and methods of making and using the same |
| TW200307011A (en) | 2002-04-18 | 2003-12-01 | Chugai Pharmaceutical Co Ltd | Hyaluronic acid modifier |
| DE60334983D1 (de) | 2002-04-30 | 2010-12-30 | Bayer Healthcare Llc | Faktor vii oder faktor viia polypeptidvarianten |
| US20060094643A1 (en) | 2002-07-03 | 2006-05-04 | Yuri Svirkin | Compositions of hyaluronic acid and methods of use |
| US7713551B2 (en) | 2002-09-11 | 2010-05-11 | Elan Pharma International Ltd. | Gel stabilized nanoparticulate active agent compositions |
| JP4092994B2 (ja) | 2002-09-13 | 2008-05-28 | ニプロ株式会社 | プレフィルドシリンジキット |
| AU2003298749A1 (en) * | 2002-11-26 | 2004-06-18 | Seacoast Neuroscience, Inc. | Buoyant polymer particles delivering therapeutic agents |
| WO2005003180A2 (en) | 2003-04-10 | 2005-01-13 | Pr Pharmaceuticals | A method for the production of emulsion-based micro particles |
| US20070207211A1 (en) | 2003-04-10 | 2007-09-06 | Pr Pharmaceuticals, Inc. | Emulsion-based microparticles and methods for the production thereof |
| AU2004259209A1 (en) | 2003-07-23 | 2005-02-03 | Pr Pharmaceuticals, Inc. | Controlled release compositions |
| US9149440B2 (en) * | 2003-09-02 | 2015-10-06 | University Of South Florida | Nanoparticles for drug-delivery |
| EP2514445B1 (en) | 2003-10-22 | 2018-07-18 | Encelle, Inc. | Bioactive hydrogel compositions for the regeneration of connective tissue |
| US20080124400A1 (en) | 2004-06-24 | 2008-05-29 | Angiotech International Ag | Microparticles With High Loadings Of A Bioactive Agent |
| US20060205733A1 (en) | 2004-08-26 | 2006-09-14 | Encysive Pharmaceuticals | Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof |
| US8034762B2 (en) | 2004-09-02 | 2011-10-11 | Cognosci, Inc. | Treatment of subarachnoid hemorrhage with Apo E analogs |
| WO2006084005A2 (en) | 2005-02-02 | 2006-08-10 | University Of Vermont And State Agricultural College | Emergence of a r-type ca2+channel(cav2.3) contributes to cerebral artery constriction following subarachnoid hemorrhage |
| WO2006091459A2 (en) | 2005-02-24 | 2006-08-31 | Joslin Diabetes Center, Inc. | Compositions and methods for treating vascular permeability |
| US20060217340A1 (en) | 2005-03-23 | 2006-09-28 | University Of Vermont And State Agricultural College | Methods and products for treating hypertension by modulation of TRPC3 channel activity |
| WO2006114105A2 (en) | 2005-04-26 | 2006-11-02 | Maxygen Holdings Ltd. | Use of modified factor vii for treating bleeding |
| US20090156481A1 (en) | 2005-07-15 | 2009-06-18 | Novo Nordisk Healthcare A/G | Use of Factor VIIa or Factor VIIa Equivalents for Preventing or Attenuating Haemorrhage Growth, and/or Oedema Generation Following Intracerebral Haemorrhage (ICH) in Patients Treated with Antiplatelet Therapy |
| GB0515492D0 (en) | 2005-07-28 | 2005-08-31 | Reckitt Benckiser Healthcare | Improvements in or relating to compositions,articles and methods |
| EP1933837A4 (en) | 2005-10-14 | 2009-07-15 | Transform Pharmaceuticals Inc | PHARMACEUTICAL LIQUID COMPOSITIONS OF NIMODIPIN |
| US20070203079A1 (en) | 2005-11-21 | 2007-08-30 | Caldwell Guy A | Methods of using small molecule compounds for neuroprotection |
| WO2008087424A1 (en) | 2007-01-18 | 2008-07-24 | Reckitt Benckiser N.V. | Dosage element and a method of manufacturing a dosage element |
| WO2008134541A2 (en) | 2007-04-25 | 2008-11-06 | Musculoskeletal Transplant Foundation | Reinforced biological mesh for surgical reinforcement |
| US9005183B2 (en) | 2007-05-16 | 2015-04-14 | Health Knight, Llc | System and method for treating erectile dysfunction |
| US8252302B2 (en) | 2007-06-11 | 2012-08-28 | Edge Therapeutics, Inc. | Methods and compositions to treat hemorrhagic conditions of the brain |
| US10092524B2 (en) | 2008-06-11 | 2018-10-09 | Edge Therapeutics, Inc. | Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage |
| NZ599430A (en) | 2007-06-11 | 2014-03-28 | Loch Macdonald R | A drug delivery system for the prevention of cerebral vasospasm |
| EP2222281B1 (en) | 2007-12-20 | 2018-12-05 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
| US20100008968A1 (en) | 2008-06-26 | 2010-01-14 | Lampe John W | Method for treating cardiovascular diseases using rho kinase inhibitor compounds |
| US8569375B2 (en) | 2008-08-22 | 2013-10-29 | Reckitt Benckiser Healthcare (Uk) Limited | Compositions |
| EP2331082B1 (en) | 2008-09-11 | 2021-01-06 | Evonik Corporation | Solvent extraction microencapsulation with tunable extraction rates |
| CA2737484C (en) | 2008-09-18 | 2017-10-10 | Surmodics Pharmaceuticals, Inc. | Microencapsulation process with solvent and salt |
| US20130059008A1 (en) | 2009-01-23 | 2013-03-07 | Jeffrey L. Atkinson | Drying methods for tuning microparticle properties |
| US20100189763A1 (en) | 2009-01-23 | 2010-07-29 | Heather Nettles | Controlled release systems from polymer blends |
| JP2012515837A (ja) | 2009-01-23 | 2012-07-12 | サーモディクス ファーマシューティカルズ, インコーポレイテッド | 異なる非反復単位を有するポリマーを含むポリマー混合物、ならびにそれを作製および使用するための方法 |
| US20100291027A1 (en) | 2009-05-14 | 2010-11-18 | Jason Campbell | Hyaluronic acid (ha) injection vehicle |
| US20110033463A1 (en) | 2009-08-06 | 2011-02-10 | Medtronic, Inc. | Apheresis, administration of agent, or combination thereof |
| JP5791629B2 (ja) | 2009-12-22 | 2015-10-07 | エボニック コーポレイションEvonik Corporation | 微粒子を調製する乳剤基調プロセス、及び、プロセスで利用されるワークヘッド構造体 |
| JP2013523752A (ja) | 2010-03-29 | 2013-06-17 | エボニック デグサ コーポレイション | 局所投与部位における医薬組成物の保持改善のための組成物および方法 |
| US9399019B2 (en) * | 2012-05-09 | 2016-07-26 | Evonik Corporation | Polymorph compositions, methods of making, and uses thereof |
-
2013
- 2013-03-11 US US13/793,767 patent/US10092524B2/en not_active Expired - Fee Related
-
2014
- 2014-03-11 CA CA2905327A patent/CA2905327A1/en not_active Abandoned
- 2014-03-11 HK HK16103935.4A patent/HK1216002A1/zh unknown
- 2014-03-11 AU AU2014248877A patent/AU2014248877A1/en not_active Abandoned
- 2014-03-11 KR KR1020157028454A patent/KR101902319B1/ko not_active Expired - Fee Related
- 2014-03-11 WO PCT/US2014/023748 patent/WO2014164904A1/en not_active Ceased
- 2014-03-11 BR BR112015022218A patent/BR112015022218A2/pt not_active IP Right Cessation
- 2014-03-11 EP EP14780318.3A patent/EP2968166A4/en not_active Withdrawn
- 2014-03-11 RU RU2015143206A patent/RU2015143206A/ru not_active Application Discontinuation
- 2014-03-11 CN CN201480026815.5A patent/CN105324108A/zh active Pending
- 2014-03-11 JP JP2016501330A patent/JP2016512527A/ja active Pending
- 2014-03-11 NZ NZ629730A patent/NZ629730A/en not_active IP Right Cessation
- 2014-03-11 GB GB1516997.2A patent/GB2528801A/en not_active Withdrawn
- 2014-03-11 SG SG11201507398XA patent/SG11201507398XA/en unknown
-
2016
- 2016-05-16 US US15/156,152 patent/US20160324796A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012109664A1 (en) * | 2011-02-11 | 2012-08-16 | Edge Therapeutics | Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage |
| WO2012138854A1 (en) * | 2011-04-05 | 2012-10-11 | Edge Therapeutics | Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow |
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015022218A2 (pt) | 2017-07-18 |
| SG11201507398XA (en) | 2015-10-29 |
| HK1216002A1 (zh) | 2016-10-07 |
| US10092524B2 (en) | 2018-10-09 |
| GB2528801A (en) | 2016-02-03 |
| AU2014248877A1 (en) | 2015-10-01 |
| EP2968166A1 (en) | 2016-01-20 |
| KR101902319B1 (ko) | 2018-09-28 |
| EP2968166A4 (en) | 2016-10-05 |
| CA2905327A1 (en) | 2014-10-09 |
| GB201516997D0 (en) | 2015-11-11 |
| US20130243864A1 (en) | 2013-09-19 |
| US20160324796A1 (en) | 2016-11-10 |
| RU2015143206A (ru) | 2017-04-18 |
| WO2014164904A1 (en) | 2014-10-09 |
| CN105324108A (zh) | 2016-02-10 |
| AU2014248877A8 (en) | 2015-10-29 |
| KR20150136084A (ko) | 2015-12-04 |
| NZ629730A (en) | 2017-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101902319B1 (ko) | 동맥류 지주막하 출혈의 합병증 치료를 위한 조성물 및 그의 용도 | |
| JP6336899B2 (ja) | 脳血流に影響する脳損傷後の結果を改善するための脳室内ドラッグデリバリーシステム | |
| KR101554250B1 (ko) | 뇌혈관 연축의 예방을 위한 약물 전달 시스템 | |
| JP6146814B2 (ja) | クモ膜下出血のヒトの予後を改善する組成物及び方法 | |
| US20190054022A1 (en) | Formulations of site-specific, microparticulate compositions and their use to improve outcome after aneursymal subarachnoid hemorrhage | |
| CA2826890A1 (en) | Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage | |
| HK1230079A1 (en) | Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage | |
| NZ613970B2 (en) | Compositions and methods for improving prognosis of a human with subarachnoid hemorrhage | |
| NZ727856B2 (en) | Intraventricular drug delivery system for improving outcome after a brain injury affecting cerebral blood flow |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170113 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170113 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170828 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171128 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180104 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180104 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180611 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20190124 |